David Dorward; Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)Amid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic now entering early clinical development. The compound BAL2420 targets LptA, part of the lipopolysaccharide transport bridge that Gram negative bacteria rely on to build their outer membrane.
Tag Archive for: Antibiotics
Image by freepikAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.